Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | Inhibition of SAMDC in HL60 cells by fluorimetric assay | ChEMBL. | 17181173 | |
Activity (functional) | 0 | Cell cycle arrest in HL60 cells by accumulation in G2/M phase | ChEMBL. | 17181173 |
Activity (functional) | 0 | Reduction in G0/G1 phase of cell cycle arrest in HL60 cells | ChEMBL. | 17181173 |
Activity (functional) | 0 | Reduction in S phase of cell cycle arrest in HL60 cells | ChEMBL. | 17181173 |
Activity (functional) | 0 | Increase in p21 level in HL60 cells at 25 uM after 24 hrs | ChEMBL. | 17181173 |
Activity (functional) | 0 | Increase in p27 level in HL60 cells at 25 uM after 24 hrs | ChEMBL. | 17181173 |
Activity (binding) | 0 | Inhibition of SAMDC in HL60 cells by fluorimetric assay | ChEMBL. | 17181173 |
Activity (functional) | = 25 % | Induction of cell death in HL60 cells at 25 uM after 48 hrs relative to control | ChEMBL. | 17181173 |
Activity (functional) | = 25 % | Induction of cell death in HL60 cells at 25 uM after 48 hrs relative to control | ChEMBL. | 17181173 |
Activity (functional) | = 45 % | Induction of cell death in HL60 cells at 50 uM within 3 hrs relative to control | ChEMBL. | 17181173 |
Activity (functional) | = 45 % | Induction of cell death in HL60 cells at 50 uM within 3 hrs relative to control | ChEMBL. | 17181173 |
Activity (functional) | = 50 % | Mitochondrial potential in HL60 cells assessed as decrease in ATP level at 25 uM after 24 hrs | ChEMBL. | 17181173 |
Activity (functional) | = 50 % | Mitochondrial potential in HL60 cells assessed as decrease in ATP level at 25 uM after 24 hrs | ChEMBL. | 17181173 |
Activity (functional) | = 52 % | Cell cycle arrest in HL60 cells by accumulation in G2/M phase at 25 uM after 72 hrs | ChEMBL. | 17181173 |
Activity (functional) | = 52 % | Cell cycle arrest in HL60 cells by accumulation in G2/M phase at 25 uM after 72 hrs | ChEMBL. | 17181173 |
Activity (functional) | = 80 % | Reduction in cell proliferation of HL60 cells at 25 uM after 48 hrs relative to control | ChEMBL. | 17181173 |
Activity (functional) | = 80 % | Reduction in cell proliferation of HL60 cells at 25 uM after 48 hrs relative to control | ChEMBL. | 17181173 |
Activity (functional) | = 100 % | Induction of cell death in HL60 cells at 50 uM after 24 hrs relative to control | ChEMBL. | 17181173 |
Activity (functional) | = 100 % | Induction of cell death in HL60 cells at 50 uM after 24 hrs relative to control | ChEMBL. | 17181173 |
GI50 (functional) | = 4.74 | Antitumor activity against NSCLC cell lines of the NCI60 panel | ChEMBL. | 17181173 |
LC50 (functional) | = 4.14 | Antitumor activity against NSCLC cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log LC50 (functional) | = 4.1 | Antitumor activity against prostate cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log LC50 (functional) | = 4.12 | Antitumor activity against CNS cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log LC50 (functional) | = 4.12 | Antitumor activity against ovarian cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log LC50 (functional) | = 4.13 | Antitumor activity against colon cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log LC50 (functional) | = 4.13 | Antitumor activity against breast cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log LC50 (functional) | = 4.14 | Antitumor activity against NSCLC cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log LC50 (functional) | = 4.19 | Antitumor activity against melanoma cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log TGI (functional) | = 4.08 | Antitumor activity against leukemia cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log TGI (functional) | = 4.24 | Antitumor activity against renal cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log TGI (functional) | = 4.24 | Antitumor activity against prostate cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log TGI (functional) | = 4.38 | Antitumor activity against CNS cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log TGI (functional) | = 4.38 | Antitumor activity against breast cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log TGI (functional) | = 4.39 | Antitumor activity against colon cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log TGI (functional) | = 4.43 | Antitumor activity against NSCLC cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log TGI (functional) | = 4.43 | Antitumor activity against ovarian cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log TGI (functional) | = 4.48 | Antitumor activity against melanoma cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Log TGI (functional) | = 4.5 | Antitumor activity against renal cell lines of the NCI60 panel | ChEMBL. | 17181173 |
pGI50 (functional) | = 4.28 | Antitumor activity against leukemia cell lines of the NCI60 panel | ChEMBL. | 17181173 |
pGI50 (functional) | = 4.64 | Antitumor activity against breast cell lines of the NCI60 panel | ChEMBL. | 17181173 |
pGI50 (functional) | = 4.65 | Antitumor activity against prostate cell lines of the NCI60 panel | ChEMBL. | 17181173 |
pGI50 (functional) | = 4.68 | Antitumor activity against CNS cell lines of the NCI60 panel | ChEMBL. | 17181173 |
pGI50 (functional) | = 4.73 | Antitumor activity against ovarian cell lines of the NCI60 panel | ChEMBL. | 17181173 |
pGI50 (functional) | = 4.74 | Antitumor activity against NSCLC cell lines of the NCI60 panel | ChEMBL. | 17181173 |
pGI50 (functional) | = 4.74 | Antitumor activity against colon cell lines of the NCI60 panel | ChEMBL. | 17181173 |
pGI50 (functional) | = 4.77 | Antitumor activity against melanoma cell lines of the NCI60 panel | ChEMBL. | 17181173 |
pGI50 (functional) | = 5.18 | Antitumor activity against renal cell lines of the NCI60 panel | ChEMBL. | 17181173 |
TGI (functional) | = 4.43 | Antitumor activity against NSCLC cell lines of the NCI60 panel | ChEMBL. | 17181173 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.